Cross-validation of the mouse and the human transcriptomic data from the NIH Accelerating Medicines Partnership–AD database demonstrated that pathways improved by the treatment in APP/PS1 mice, including the immune system response and neurotransmission, represent mechanisms essential for therapeutic ...
For assessing the effect of excluding an exogenous construct from the model, the use of the effect size (f2) is necessary, as proposed by [54]. The measurement of each construct can result in small, medium, or large effect sizes, as respectively indicated by values around 0.02, 0.15, or...